|
Gyros AB announced today the introduction of a new
CD microlaboratory, Gyrolab˛ MALDI IMAC.
Maris Hartmanis, President and CEO of Gyros AB explained,
"Successful identification of proteins, especially those in low
abundance, is crucial in proteomics and detection and identification
of phosphorylated proteins is often a particular challenge. Gyrolab
MALDI IMAC will offer users a unique solution for detection of
phosphorylated peptides by MALDI mass spectrometry."
This new method offers a smoother, more reliable solution as
compared to the mainly manual preparation options currently available.
Protein digests are prepared in duplicate (2 x 48) on Gyrolab MALDI
IMAC. Phosphorylated peptides are concentrated, purified and
crystallized directly onto MALDI target areas on the CD. Each
duplicate sample is subjected to the same process, but with the
addition of an enzymatic step that should remove any phosphate groups
before crystallization. The CD is transferred to MALDI MS for
analysis. Phosphorylated peptides are detected by comparing mass
spectra from phosphorylated and dephosphorylated samples. Any shifts
in mass indicate that the peaks had contained phosphate groups before
the enzymatic treatment.
Gyrolab Workstation controls each run through a specific software
method, transferring samples and reagents into the microlaboratory and
spinning the CD to drive up to 96 samples in parallel through each
preparation step.
Dr. Hartmanis added, "Users of our Gyrolab MALDI solution already
see the benefits of Gyrolab MALDI SP1, our first CD microlaboratory
that offers two alternative sample preparation methods prior to MALDI
MS. We are glad to add a second CD to our Gyrolab MALDI offering.
Providing an increasing number of preparation options not only
benefits Gyrolab MALDI users, but also demonstrates the flexibility
and strength of Gyros technology platform".
Gyros miniaturizes and integrates laboratory applications, enabling
scientists to generate more information from less sample and to
improve lab performance. Using our proprietary technology platform, we
increase productivity by streamlining the many steps of conventional
applications into single, nanoliter scale procedures. Optimal
environments are created for each application.
A Gyrolab microlaboratory, in the form of a compact disk, can process
hundreds of samples in parallel, under the control of Gyrolab
Workstation.
Our company will realize the full potential of the Gyros technology
platform in the fields of drug discovery and diagnostics. Initial
product offerings are focused towards the growing area of proteomics.
Gyros has more than 90 employees working at its headquarters in
Uppsala Science Park, Sweden and in sales offices in the USA and
Europe.
Maris Hartmanis, President and CEO, Gyros AB
Tel: +46 (0)18 566 330
Mobile: +46 (0)70 562 86 17
Email: maris.hartmanis@gyros.com
Per Sjöberg, Executive Vice President Commercial Operations, Gyros AB
Tel: +46 (0)18 566 318
Mobile: +46 (0)70 544 47 99
Email: per.sjoberg@gyros.com
Sue Cresswell, Marketing Communications
Tel: +46 (0)8 54472620
Mobile: +46 (0)70 551 9520
Email: sue.cresswell@gyros.com
Statements in this press release that are not strictly historical may
be forward-looking and include risks and uncertainties. Therefore,
though based on Gyros' current expectations, it should be duly noted
that a variety of factors could cause actual results and experiences
to differ materially from what is herein expressed. Risks and
uncertainties include, but are not limited to, risks associated with
the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully develop,
adapt, produce or commercialize products, the ability to identify and
develop new products and to differentiate products from those of
competitors, as well as various legal hazards.
|
|
